Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease

Francisco Lopez, Pablo Parker, Auayporn Nademanee, Roberto Rodriguez, Zaid S Al-Kadhimi, Ravi Bhatia, Sandra Cohen, Peter Falk, Henry Fung, Mark Kirschbaum, Amrita Krishnan, Neil Kogut, Arturo Molina, Ryotaro Nakamura, Margaret O'Donnell, Leslie Popplewell, Vinod Pullarkat, Joseph Rosenthal, Firoozeh Sahebi, Eileen Smith & 7 others David Snyder, George Somlo, Ricardo Spielberger, Anthony Stein, Robert Sweetman, Jasmine Zain, Stephen Forman

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Current treatment of chronic graft-versus-host disease (cGVHD) with prednisone (PSE) alone or with added cyclosporine or tacrolimus still has a very high failure and complication rate, and new treatment approaches are needed for both primary and salvage therapy. Mycophenolate mofetil (MMF) is an immunosuppressive agent currently in use for acute graft-versus-host disease prophylaxis. To determine whether MMF had activity in the treatment of cGVHD, we added MMF to standard cyclosporine, tacrolimus, and/or PSE as salvage/second-line (n = 24) or first-line (n = 10) therapy in 34 patients. Nine (90%) of 10 patients receiving first-line and 18 (75%) of 24 receiving second-line MMF therapy responded. Twelve (35%) patients had a complete remission, 15 (44%) had a partial remission, 5 (15%) had stable disease, and only 2 (6%) had progressive disease. Out of 30 patients receiving PSE, 22 (73%) were able to decrease PSE doses (median decrease of 50%; range, 25%-100%). With a median follow-up of 24 months (range, 6-28 months), 29 (85%) patients are alive. Three patients had to discontinue MMF because of abdominal cramps within 3 months of starting treatment. These data suggest that MMF is an active, well-tolerated agent in the treatment of cGVHD and may have a beneficial effect on the survival of patients with this complication.

Original languageEnglish (US)
Pages (from-to)307-313
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Volume11
Issue number4
DOIs
StatePublished - Apr 1 2005

Fingerprint

Mycophenolic Acid
Graft vs Host Disease
Prednisone
Tacrolimus
Therapeutics
Cyclosporine
Salvage Therapy
Colic
Immunosuppressive Agents
Survival

Keywords

  • Chronic graft-versus-host disease
  • Mycophenolate mofetil
  • Transplantations

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease. / Lopez, Francisco; Parker, Pablo; Nademanee, Auayporn; Rodriguez, Roberto; Al-Kadhimi, Zaid S; Bhatia, Ravi; Cohen, Sandra; Falk, Peter; Fung, Henry; Kirschbaum, Mark; Krishnan, Amrita; Kogut, Neil; Molina, Arturo; Nakamura, Ryotaro; O'Donnell, Margaret; Popplewell, Leslie; Pullarkat, Vinod; Rosenthal, Joseph; Sahebi, Firoozeh; Smith, Eileen; Snyder, David; Somlo, George; Spielberger, Ricardo; Stein, Anthony; Sweetman, Robert; Zain, Jasmine; Forman, Stephen.

In: Biology of Blood and Marrow Transplantation, Vol. 11, No. 4, 01.04.2005, p. 307-313.

Research output: Contribution to journalArticle

Lopez, F, Parker, P, Nademanee, A, Rodriguez, R, Al-Kadhimi, ZS, Bhatia, R, Cohen, S, Falk, P, Fung, H, Kirschbaum, M, Krishnan, A, Kogut, N, Molina, A, Nakamura, R, O'Donnell, M, Popplewell, L, Pullarkat, V, Rosenthal, J, Sahebi, F, Smith, E, Snyder, D, Somlo, G, Spielberger, R, Stein, A, Sweetman, R, Zain, J & Forman, S 2005, 'Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease', Biology of Blood and Marrow Transplantation, vol. 11, no. 4, pp. 307-313. https://doi.org/10.1016/j.bbmt.2005.01.011
Lopez, Francisco ; Parker, Pablo ; Nademanee, Auayporn ; Rodriguez, Roberto ; Al-Kadhimi, Zaid S ; Bhatia, Ravi ; Cohen, Sandra ; Falk, Peter ; Fung, Henry ; Kirschbaum, Mark ; Krishnan, Amrita ; Kogut, Neil ; Molina, Arturo ; Nakamura, Ryotaro ; O'Donnell, Margaret ; Popplewell, Leslie ; Pullarkat, Vinod ; Rosenthal, Joseph ; Sahebi, Firoozeh ; Smith, Eileen ; Snyder, David ; Somlo, George ; Spielberger, Ricardo ; Stein, Anthony ; Sweetman, Robert ; Zain, Jasmine ; Forman, Stephen. / Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease. In: Biology of Blood and Marrow Transplantation. 2005 ; Vol. 11, No. 4. pp. 307-313.
@article{cb07398cdf824d8680459c1ba369a0ea,
title = "Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease",
abstract = "Current treatment of chronic graft-versus-host disease (cGVHD) with prednisone (PSE) alone or with added cyclosporine or tacrolimus still has a very high failure and complication rate, and new treatment approaches are needed for both primary and salvage therapy. Mycophenolate mofetil (MMF) is an immunosuppressive agent currently in use for acute graft-versus-host disease prophylaxis. To determine whether MMF had activity in the treatment of cGVHD, we added MMF to standard cyclosporine, tacrolimus, and/or PSE as salvage/second-line (n = 24) or first-line (n = 10) therapy in 34 patients. Nine (90{\%}) of 10 patients receiving first-line and 18 (75{\%}) of 24 receiving second-line MMF therapy responded. Twelve (35{\%}) patients had a complete remission, 15 (44{\%}) had a partial remission, 5 (15{\%}) had stable disease, and only 2 (6{\%}) had progressive disease. Out of 30 patients receiving PSE, 22 (73{\%}) were able to decrease PSE doses (median decrease of 50{\%}; range, 25{\%}-100{\%}). With a median follow-up of 24 months (range, 6-28 months), 29 (85{\%}) patients are alive. Three patients had to discontinue MMF because of abdominal cramps within 3 months of starting treatment. These data suggest that MMF is an active, well-tolerated agent in the treatment of cGVHD and may have a beneficial effect on the survival of patients with this complication.",
keywords = "Chronic graft-versus-host disease, Mycophenolate mofetil, Transplantations",
author = "Francisco Lopez and Pablo Parker and Auayporn Nademanee and Roberto Rodriguez and Al-Kadhimi, {Zaid S} and Ravi Bhatia and Sandra Cohen and Peter Falk and Henry Fung and Mark Kirschbaum and Amrita Krishnan and Neil Kogut and Arturo Molina and Ryotaro Nakamura and Margaret O'Donnell and Leslie Popplewell and Vinod Pullarkat and Joseph Rosenthal and Firoozeh Sahebi and Eileen Smith and David Snyder and George Somlo and Ricardo Spielberger and Anthony Stein and Robert Sweetman and Jasmine Zain and Stephen Forman",
year = "2005",
month = "4",
day = "1",
doi = "10.1016/j.bbmt.2005.01.011",
language = "English (US)",
volume = "11",
pages = "307--313",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease

AU - Lopez, Francisco

AU - Parker, Pablo

AU - Nademanee, Auayporn

AU - Rodriguez, Roberto

AU - Al-Kadhimi, Zaid S

AU - Bhatia, Ravi

AU - Cohen, Sandra

AU - Falk, Peter

AU - Fung, Henry

AU - Kirschbaum, Mark

AU - Krishnan, Amrita

AU - Kogut, Neil

AU - Molina, Arturo

AU - Nakamura, Ryotaro

AU - O'Donnell, Margaret

AU - Popplewell, Leslie

AU - Pullarkat, Vinod

AU - Rosenthal, Joseph

AU - Sahebi, Firoozeh

AU - Smith, Eileen

AU - Snyder, David

AU - Somlo, George

AU - Spielberger, Ricardo

AU - Stein, Anthony

AU - Sweetman, Robert

AU - Zain, Jasmine

AU - Forman, Stephen

PY - 2005/4/1

Y1 - 2005/4/1

N2 - Current treatment of chronic graft-versus-host disease (cGVHD) with prednisone (PSE) alone or with added cyclosporine or tacrolimus still has a very high failure and complication rate, and new treatment approaches are needed for both primary and salvage therapy. Mycophenolate mofetil (MMF) is an immunosuppressive agent currently in use for acute graft-versus-host disease prophylaxis. To determine whether MMF had activity in the treatment of cGVHD, we added MMF to standard cyclosporine, tacrolimus, and/or PSE as salvage/second-line (n = 24) or first-line (n = 10) therapy in 34 patients. Nine (90%) of 10 patients receiving first-line and 18 (75%) of 24 receiving second-line MMF therapy responded. Twelve (35%) patients had a complete remission, 15 (44%) had a partial remission, 5 (15%) had stable disease, and only 2 (6%) had progressive disease. Out of 30 patients receiving PSE, 22 (73%) were able to decrease PSE doses (median decrease of 50%; range, 25%-100%). With a median follow-up of 24 months (range, 6-28 months), 29 (85%) patients are alive. Three patients had to discontinue MMF because of abdominal cramps within 3 months of starting treatment. These data suggest that MMF is an active, well-tolerated agent in the treatment of cGVHD and may have a beneficial effect on the survival of patients with this complication.

AB - Current treatment of chronic graft-versus-host disease (cGVHD) with prednisone (PSE) alone or with added cyclosporine or tacrolimus still has a very high failure and complication rate, and new treatment approaches are needed for both primary and salvage therapy. Mycophenolate mofetil (MMF) is an immunosuppressive agent currently in use for acute graft-versus-host disease prophylaxis. To determine whether MMF had activity in the treatment of cGVHD, we added MMF to standard cyclosporine, tacrolimus, and/or PSE as salvage/second-line (n = 24) or first-line (n = 10) therapy in 34 patients. Nine (90%) of 10 patients receiving first-line and 18 (75%) of 24 receiving second-line MMF therapy responded. Twelve (35%) patients had a complete remission, 15 (44%) had a partial remission, 5 (15%) had stable disease, and only 2 (6%) had progressive disease. Out of 30 patients receiving PSE, 22 (73%) were able to decrease PSE doses (median decrease of 50%; range, 25%-100%). With a median follow-up of 24 months (range, 6-28 months), 29 (85%) patients are alive. Three patients had to discontinue MMF because of abdominal cramps within 3 months of starting treatment. These data suggest that MMF is an active, well-tolerated agent in the treatment of cGVHD and may have a beneficial effect on the survival of patients with this complication.

KW - Chronic graft-versus-host disease

KW - Mycophenolate mofetil

KW - Transplantations

UR - http://www.scopus.com/inward/record.url?scp=20144388150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20144388150&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2005.01.011

DO - 10.1016/j.bbmt.2005.01.011

M3 - Article

VL - 11

SP - 307

EP - 313

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 4

ER -